Masterson et al. [1] have presented the third randomized controlled trial (RCT) on platelet-rich-plasma (PRP) and erectile dysfunction (ED). Men with vasculogenic ED were assigned to intracavernosal PRP injections (n = 28) or placebo (n = 33). No significant differences were noted between the arms: 58.3%, 41.7%, and 60% of the PRP group, and 53.6%, 52%, and 41.7% of the placebo group met the minimal clinically important difference (MCID) for the International Index of Erectile Function-Erectile Function (IIEF-EF) scale at 1, 3, and 6 mo, respectively. The findings are in contrast to two previous RCTs and the inconsistencies necessitate a closer examination of the studies.